SG11202002460QA - Selective p2x3 modulators - Google Patents
Selective p2x3 modulatorsInfo
- Publication number
- SG11202002460QA SG11202002460QA SG11202002460QA SG11202002460QA SG11202002460QA SG 11202002460Q A SG11202002460Q A SG 11202002460QA SG 11202002460Q A SG11202002460Q A SG 11202002460QA SG 11202002460Q A SG11202002460Q A SG 11202002460QA SG 11202002460Q A SG11202002460Q A SG 11202002460QA
- Authority
- SG
- Singapore
- Prior art keywords
- modulators
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560077P | 2017-09-18 | 2017-09-18 | |
| US15/936,316 US10111883B1 (en) | 2017-09-18 | 2018-03-26 | Selective P2X3 modulators |
| PCT/IB2018/001513 WO2019064079A2 (en) | 2017-09-18 | 2018-09-14 | Selective p2x3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002460QA true SG11202002460QA (en) | 2020-04-29 |
Family
ID=63894683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002460QA SG11202002460QA (en) | 2017-09-18 | 2018-09-14 | Selective p2x3 modulators |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US10111883B1 (en) |
| EP (2) | EP3684368B8 (en) |
| JP (1) | JP7242681B2 (en) |
| KR (1) | KR20200092938A (en) |
| CN (1) | CN111601601A (en) |
| AU (1) | AU2018342751B2 (en) |
| CA (1) | CA3076150C (en) |
| IL (2) | IL273348B2 (en) |
| MX (1) | MX2020002968A (en) |
| SG (1) | SG11202002460QA (en) |
| WO (1) | WO2019064079A2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019353424B2 (en) * | 2018-10-05 | 2022-12-08 | Shionogi & Co., Ltd. | Medicine for treating chronic cough |
| MX2021003987A (en) * | 2018-10-10 | 2021-06-23 | Bellus Health Cough Inc | Treatment of pruritus with p2x3 antagonists. |
| EP3880678A4 (en) * | 2018-11-13 | 2022-08-31 | Bellus Health Cough Inc. | Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator |
| SG11202106706TA (en) * | 2018-12-29 | 2021-07-29 | Wuhan Ll Science And Technology Development Co Ltd | Heterocyclic compound intermediate, preparation method therefor and application thereof |
| CN113727716A (en) * | 2019-02-25 | 2021-11-30 | 贝卢斯医疗咳嗽病公司 | Treatment with P2X3 modulators |
| CN112409331B (en) * | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | Heterocyclic derivative inhibitor, preparation method and application thereof |
| JP2023513373A (en) * | 2020-02-14 | 2023-03-30 | べルス・ヘルス・コフ・インコーポレーテッド | P2X3 modulators |
| CN114085220B (en) * | 2020-06-22 | 2023-06-16 | 上海海雁医药科技有限公司 | Substituted morpholine-4-carboxylic acid ester derivatives, compositions and pharmaceutical uses thereof |
| CN113929677A (en) * | 2020-06-29 | 2022-01-14 | 武汉朗来科技发展有限公司 | Crystal form of heterocyclic compound, preparation method and application thereof |
| CN113912601B (en) * | 2020-07-10 | 2023-06-06 | 上海拓界生物医药科技有限公司 | Novel imidazo [1,2-a ] pyridine derivatives, preparation method and medical application thereof |
| EP4198034A4 (en) * | 2020-08-13 | 2024-01-17 | Tuojie Biotech Shanghai Co Ltd | Benzimidazole derivatives, preparation method therefor and medical use thereof |
| CN116635389A (en) * | 2021-01-29 | 2023-08-22 | 上海海雁医药科技有限公司 | Morpholine derivative, pharmaceutical composition and application thereof |
| WO2022258059A1 (en) * | 2021-06-10 | 2022-12-15 | 武汉朗来科技发展有限公司 | Pharmaceutical composition, preparation, and preparation method therefor and use thereof |
| WO2023020156A1 (en) * | 2021-08-20 | 2023-02-23 | 苏州璞正医药有限公司 | P2x3 receptor-selective modulator of imidazopyridine derivative and pharmaceutical use thereof |
| US20230218661A1 (en) * | 2022-01-10 | 2023-07-13 | Sensory Cloud, Inc. | Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011062550A1 (en) * | 2009-11-18 | 2011-05-26 | Astrazeneca Ab | Benzoimidazole compounds and uses thereof |
| CA2898665C (en) * | 2013-01-31 | 2021-02-16 | Neomed Institute | Imidazopyridine compounds and their use as p2x purinoreceptor modulators |
| MX367657B (en) | 2013-08-23 | 2019-08-30 | Afferent Pharmaceuticals Inc | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough. |
| RS64155B1 (en) * | 2015-09-29 | 2023-05-31 | Afferent Pharmaceuticals Inc | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| CN116854693A (en) * | 2016-09-30 | 2023-10-10 | 阿沙纳生物科学公司 | P2X 3 And/or P2X 2/3 Compounds and methods |
-
2018
- 2018-03-26 US US15/936,316 patent/US10111883B1/en active Active
- 2018-09-14 AU AU2018342751A patent/AU2018342751B2/en active Active
- 2018-09-14 CA CA3076150A patent/CA3076150C/en active Active
- 2018-09-14 EP EP18860273.4A patent/EP3684368B8/en active Active
- 2018-09-14 US US16/647,821 patent/US20200230148A1/en not_active Abandoned
- 2018-09-14 CN CN201880073147.XA patent/CN111601601A/en active Pending
- 2018-09-14 JP JP2020537064A patent/JP7242681B2/en active Active
- 2018-09-14 MX MX2020002968A patent/MX2020002968A/en unknown
- 2018-09-14 IL IL273348A patent/IL273348B2/en unknown
- 2018-09-14 SG SG11202002460QA patent/SG11202002460QA/en unknown
- 2018-09-14 WO PCT/IB2018/001513 patent/WO2019064079A2/en unknown
- 2018-09-14 KR KR1020207010982A patent/KR20200092938A/en not_active Application Discontinuation
- 2018-09-14 IL IL303257A patent/IL303257A/en unknown
- 2018-09-14 EP EP23219770.7A patent/EP4331669A3/en active Pending
-
2020
- 2020-11-17 US US16/950,742 patent/US20210069201A1/en not_active Abandoned
-
2021
- 2021-06-29 US US17/362,063 patent/US20210322432A1/en not_active Abandoned
-
2022
- 2022-02-11 US US17/669,806 patent/US20220160724A1/en not_active Abandoned
- 2022-09-14 US US17/932,200 patent/US20230248736A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018342751A1 (en) | 2020-04-23 |
| US10111883B1 (en) | 2018-10-30 |
| US20210069201A1 (en) | 2021-03-11 |
| MX2020002968A (en) | 2020-08-17 |
| IL303257A (en) | 2023-07-01 |
| US20200230148A1 (en) | 2020-07-23 |
| EP3684368B1 (en) | 2024-01-03 |
| CA3076150C (en) | 2024-01-02 |
| WO2019064079A2 (en) | 2019-04-04 |
| AU2018342751B2 (en) | 2023-06-15 |
| US20230248736A1 (en) | 2023-08-10 |
| JP2020534355A (en) | 2020-11-26 |
| US20210322432A1 (en) | 2021-10-21 |
| EP3684368A2 (en) | 2020-07-29 |
| WO2019064079A3 (en) | 2019-05-16 |
| CA3076150A1 (en) | 2019-04-04 |
| IL273348B1 (en) | 2023-07-01 |
| IL273348A (en) | 2020-05-31 |
| EP4331669A3 (en) | 2024-05-01 |
| EP3684368A4 (en) | 2021-05-26 |
| US20220160724A1 (en) | 2022-05-26 |
| CN111601601A (en) | 2020-08-28 |
| IL273348B2 (en) | 2023-11-01 |
| KR20200092938A (en) | 2020-08-04 |
| EP3684368B8 (en) | 2024-02-14 |
| EP4331669A2 (en) | 2024-03-06 |
| JP7242681B2 (en) | 2023-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273348A (en) | Selective p2x3 modulators | |
| DK3506981T3 (en) | Et transportabelt automatiseret eksternt defibrillator-apparat til engangsbrug | |
| DK3410992T3 (en) | Tilbagetrækkeligt udløb til stomipose | |
| ZA201707966B (en) | Ccr2 modulators | |
| DK3770053T3 (en) | Batterilås til en elcykel | |
| PL3303291T3 (en) | Ror-gamma modulators | |
| DK3456957T3 (en) | Modvægtssystem til balanceret navvindmølleinstallation | |
| DK3343955T3 (en) | Anordning til et høreapparat | |
| PL3303293T3 (en) | Ror-gamma modulators | |
| PL3303290T3 (en) | Ror-gamma modulators | |
| IL251067A0 (en) | P2x7 modulators | |
| DK3457555T3 (en) | Drev til et transportsystem | |
| GB201716468D0 (en) | Modulators | |
| PL3319942T3 (en) | Ror-gamma modulators | |
| IL266261A (en) | Ror-gamma modulators | |
| DK3688240T3 (en) | Konstruktionssystem til et bygningsmodul | |
| EP3648818C0 (en) | Spacer | |
| DK3481437T3 (en) | Precursorer til radiofluorering | |
| DK3726976T3 (en) | Klimareguleringssystem til insektopdræt | |
| GB201703036D0 (en) | Methods | |
| SG11201911553VA (en) | Adsorption method | |
| DK3430280T3 (en) | Magnetisk leje til en turbomaskine | |
| GB2563095B (en) | Modulators | |
| DK3615520T3 (en) | Methods | |
| DK3558418T3 (en) | Et infusionssystem til kortlivede radiofarmaceutika |